Cervical response to vaccination against HPV16 E7 in case of severe dysplasia

Simon, Philippe; Buxant, Frédéric; Hallez, Sophie; Burny, Arsène; Fayt, Isabelle; Anaf, Vincent; Noël, Jean Christophe

doi:10.1016/s0301-2115(03)00093-9

Cited by 13 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CIN3 patients underwent conization 4 weeks after the last vaccination and CIN1 patients were followed up at close intervals, except for two women with persistent cytological atypia who were treated either by laser or by conization 6 months after vaccination. The vaccine was well tolerated by all the patients with no serious adverse events either reported or detected ( [33] and data not shown).…”

Section: Resultsmentioning

confidence: 92%

“…The eligibility criteria for CIN1 patients were the persistence of a low-grade squamous intraepithelial lesion as diagnosed by cytological examination and biopsy-proven CIN1 for a minimum of 3 months with detection of oncogenic HPV (detected by Hybrid Capture II System, Digene, Gaithersburg, MD, USA). The eligibility criteria for CIN3 patients have been previously described [33]. Briefly, they had highgrade squamous intraepithelial lesion as diagnosed by single-layer cytology and biopsy-proven CIN3.…”

Section: Subjectsmentioning

confidence: 99%

“…A total of eleven patients, ages 20-51, were enrolled after providing signed informed consent. One patient was withdrawn before the end of the study [33].…”

Section: Subjectsmentioning

confidence: 99%

See 2 more Smart Citations

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein?based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

Hallez

Simon

Maudoux

et al. 2004

Cancer Immunology, Immunotherapy

104

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 92%

Section: Subjectsmentioning

confidence: 99%

See 1 more Smart Citation

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein?based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

Hallez

Simon

Maudoux

et al. 2004

Cancer Immunology, Immunotherapy

104

View full text Add to dashboard Cite

show abstract

“…Following vaccination, no viral clearance or lesion regression was detected in CIN3 patients. This could be due to the fact that histological assessment took place early and the induction of only low-level immunization (27).…”

Section: Peptide/protein-based Vaccinesmentioning

confidence: 99%

Targeted immunotherapy of high‑grade cervical intra‑epithelial neoplasia: Expectations from clinical trials (Review)

et al. 2017

View full text Add to dashboard Cite

Abstract. Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia (CIN) has been developed as an alternative to conization, to preserve future reproductive outcomes and avoid human papillomavirus (HPV) persistence. The objectives of the review are to present drugs according to their process of development and to examine their potential future use. A search for key words associated with CIN and targeted immunotherapy was carried out in the Cochrane library, Pubmed, Embase, and ClinicalTrials.gov from 1990 to 2016. Publications (randomized, prospective and retrospective studies) in any language were eligible for inclusion, as well as ongoing trials registered on the ClinicalTrials.gov website. Targeted immunotherapy includes peptide/protein-based vaccines, nucleic acid-based vaccines (DNA), and live vector-based vaccines (bacterial or viral). A total of 18 vaccines were identified for treatment of CIN at various stages of development, and the majority were well-tolerated. Adverse effects were primarily injection site reactions and flu-like symptoms under grade 2. The efficacy of vaccines defined by regression of CIN2/3 to no CIN or CIN1 ranged from 17 to 59% following a minimum of a 12-week follow-up. In the majority of studies, there was no association demonstrated between histological response and HPV clearance, or between histological or virological response and immune T cell response. Given that the spontaneous regression of CIN2/3 is 20-25% at 6 months, targeted immunotherapy occurs an additional value, which never reaches 50%, with one trial an exception to this. However, research and development on HPV eradication drugs needs to be encouraged, due to HPV-associated disease burden. Content

show abstract

“…In a first clinical study, five patients with HPV16 positive, histologically demonstrated severe cervical dysplasia (CIN III) received three doses of the vaccine four weeks apart (within two months) before conization (removal of the lesions) was performed. Histological analysis of the biopsies showed CD4+ and CD8+ T cell infiltration and a limited degree of regression [81]. In a second phase I/II clinical trial seven patients, five with CIN III and two with CIN I, received three i.m.…”

Section: Innate and Acquired Immune Responses To Hpvmentioning

confidence: 99%

Therapeutic Vaccines Against Human Papillomavirus and Cervical Cancer

Cid-Arregui¹

2009

TOVJ

View full text Add to dashboard Cite

Cervical cancer and its precursor intra-epithelial lesions are linked to infection by a subset of so-called “highrisk” human papillomavirus types, which are estimated to infect nearly four hundred million women worldwide. Two prophylactic vaccines have been commercialized recently targeting HPV16 and 18, the most prevalent viral types found in cervical cancer, which operate through induction of capsid-specific neutralizing antibodies. However, in patients with persistent infection these vaccines have not been found to protect against progression to neoplasia. Attempts are being made to develop therapeutic vaccines targeting nonstructural early viral proteins. Among these, E6 and E7 are the preferred targets, since they are essential for induction and maintenance of the malignant phenotype and are constitutively expressed by the transformed epithelial cells. Here are reviewed the most relevant potential vaccines based on HPV early antigens that have shown efficacy in preclinical models and that are being tested in clinical studies, which should determine their therapeutic capacity for eradicating HPV-induced premalignant and malignant lesions and cure cervical cancer.

show abstract

Cervical response to vaccination against HPV16 E7 in case of severe dysplasia

Cited by 13 publications

References 20 publications

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein?based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein?based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

Targeted immunotherapy of high‑grade cervical intra‑epithelial neoplasia: Expectations from clinical trials (Review)

Therapeutic Vaccines Against Human Papillomavirus and Cervical Cancer

Contact Info

Product

Resources

About